Literature DB >> 24222267

A review of the advancements in probiotic delivery: Conventional vs. non-conventional formulations for intestinal flora supplementation.

Mershen Govender1, Yahya E Choonara, Pradeep Kumar, Lisa C du Toit, Sandy van Vuuren, Viness Pillay.   

Abstract

Probiotic delivery systems are widely used nutraceutical products for the supplementation of natural intestinal flora. These delivery systems vary greatly in effectiveness to exert health benefits for a patient. Probiotic delivery systems can be categorized into conventional, pharmaceutical formulations, and non-conventional, mainly commercial food-based, products. The degree of health benefits provided by these probiotic formulations varies in their ability to deliver viable, functional bacteria in large enough numbers (effectiveness), to provide protection against the harsh effects of the gastric environment and intestinal bile (in vivo protection), and to survive formulation processes (viability). This review discusses the effectiveness of these probiotic delivery systems to deliver viable functional bacteria focusing on the ability to protect the encapsulated probiotics during formulation process as well as against harsh physiological conditions through formulation enhancements using coatings and polymer enhancements. A brief overview on the health benefits of probiotics, current formulation, patient and legal issues facing probiotic delivery, and possible recommendations for the enhanced delivery of probiotic bacteria are also provided. Newer advanced in vitro analyses that can accurately determine the effectiveness of a probiotic formulation are also discussed with an ideal probiotic delivery system hypothesized through a combination of the two probiotic delivery systems described.

Entities:  

Mesh:

Year:  2013        PMID: 24222267      PMCID: PMC3909163          DOI: 10.1208/s12249-013-0027-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  73 in total

Review 1.  Prophylactic and therapeutic uses of probiotics: a review.

Authors:  L Kopp-Hoolihan
Journal:  J Am Diet Assoc       Date:  2001-02

2.  Probiotics: functionality and commercial status.

Authors:  S Scheinbach
Journal:  Biotechnol Adv       Date:  1998-05       Impact factor: 14.227

Review 3.  Probiotics: from research to consumer.

Authors:  M Del Piano; L Morelli; G P Strozzi; S Allesina; M Barba; F Deidda; P Lorenzini; M Ballaré; F Montino; M Orsello; M Sartori; E Garello; S Carmagnola; M Pagliarulo; L Capurso
Journal:  Dig Liver Dis       Date:  2006-12       Impact factor: 4.088

Review 4.  Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier.

Authors:  Christian Buddenborg; Damini Daudel; Shanti Liebrecht; Lilo Greune; Verena Humberg; M Alexander Schmidt
Journal:  Int J Med Microbiol       Date:  2007-10-23       Impact factor: 3.473

5.  Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis.

Authors:  J S Zhou; H S Gill
Journal:  Int J Food Microbiol       Date:  2005-08-15       Impact factor: 5.277

Review 6.  Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.

Authors:  Robert Penner; Richard N Fedorak; Karen L Madsen
Journal:  Curr Opin Pharmacol       Date:  2005-10-07       Impact factor: 5.547

7.  Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations.

Authors:  Carmen Calinescu; Jérôme Mulhbacher; Eric Nadeau; John Morris Fairbrother; Mircea Alexandru Mateescu
Journal:  Eur J Pharm Biopharm       Date:  2005-05       Impact factor: 5.571

8.  Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study.

Authors:  Jennifer A J Madden; Susan F Plummer; James Tang; Iveta Garaiova; Nigel T Plummer; Mary Herbison; John O Hunter; Takashi Shimada; Lei Cheng; Taro Shirakawa
Journal:  Int Immunopharmacol       Date:  2005-06       Impact factor: 4.932

9.  Carboxymethyl high amylose starch for F4 fimbriae gastro-resistant oral formulation.

Authors:  Carmen Calinescu; Eric Nadeau; Jérome Mulhbacher; John Morris Fairbrother; Mircea-Alexandru Mateescu
Journal:  Int J Pharm       Date:  2007-04-24       Impact factor: 5.875

10.  Effect of different prebiotics on the fermentation kinetics, probiotic survival and fatty acids profiles in nonfat symbiotic fermented milk.

Authors:  Ricardo P S Oliveira; Ana C R Florence; Roberta C Silva; Patrizia Perego; Attilio Converti; Luiz A Gioielli; Maricê N Oliveira
Journal:  Int J Food Microbiol       Date:  2008-10-20       Impact factor: 5.277

View more
  21 in total

Review 1.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 2.  Insights on the Critical Parameters Affecting the Probiotic Viability During Stabilization Process and Formulation Development.

Authors:  Sharda Gurram; Durgesh K Jha; Devanshi S Shah; Madhuri M Kshirsagar; Purnima D Amin
Journal:  AAPS PharmSciTech       Date:  2021-05-18       Impact factor: 3.246

3.  Adhesion Capacity of Weissella cibaria to Bovine Mammary Tissue and the Effect of Bio-Sealant Topical Application on Physicochemical Properties of Milk.

Authors:  Liliana Serna-Cock; Omar Vladimir Pabón-Rodríguez; Gloria Inés Giraldo-Gómez
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

Review 4.  Update on the Gastrointestinal Microbiome in Systemic Sclerosis.

Authors:  Chiara Bellocchi; Elizabeth R Volkmann
Journal:  Curr Rheumatol Rep       Date:  2018-06-25       Impact factor: 4.592

5.  Microencapsulation May Preserve the Viability of Probiotic Bacteria During a Baking Process and Digestion: A Case Study with Bifidobacterium animalis Subsp. lactis in Bread.

Authors:  Adel Penhasi; Albert Reuveni; Israel Baluashvili
Journal:  Curr Microbiol       Date:  2021-01-03       Impact factor: 2.188

6.  A Dual-Biotic System for the Concurrent Delivery of Antibiotics and Probiotics: In Vitro, Ex Vivo, In Vivo and In Silico Evaluation and Correlation.

Authors:  Mershen Govender; Yahya E Choonara; Sandy van Vuuren; Pradeep Kumar; Lisa C du Toit; Kennedy Erlwanger; Viness Pillay
Journal:  Pharm Res       Date:  2016-09-06       Impact factor: 4.200

7.  An adaptable and non-invasive method for tracking Bifidobacterium animalis subspecies lactis 420 in the mouse gut.

Authors:  Marissa A Lopez-Pier; Matthew P Koppinger; Preston R Harris; Danielle K Cannon; Rinku S Skaria; Bonnie L Hurwitz; George Watts; Shravan Aras; Marvin J Slepian; John P Konhilas
Journal:  J Microbiol Methods       Date:  2021-08-13       Impact factor: 2.622

8.  Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.

Authors:  Toufic A Kabbani; Kumar Pallav; Scot E Dowd; Javier Villafuerte-Galvez; Rohini R Vanga; Natalia E Castillo; Joshua Hansen; Melinda Dennis; Daniel A Leffler; Ciarán P Kelly
Journal:  Gut Microbes       Date:  2016-12-14

Review 9.  Emerging Trends in "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications.

Authors:  Racha El Hage; Emma Hernandez-Sanabria; Tom Van de Wiele
Journal:  Front Microbiol       Date:  2017-09-29       Impact factor: 5.640

10.  Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome.

Authors:  Thomas E Ichim; Amit N Patel; Kim A Shafer
Journal:  J Transl Med       Date:  2016-06-22       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.